Group overview

Drug Delivery Partnerships

Email this page

This group is a drug delivery partnerships meeting place, focusing on bringing together professionals seeking the latest strategies, industry updates, and networking opportunities to help position your company for a successful partnership/collaboration.

(1 post)

Improve Cancer Therapies Through Nano-Reformulation

  • Ryan Geswell

    At Drug Delivery Partnerships 2015 ( ) – Scott E. McNeil, PhD, Nanotechnology Characterization Lab (NCL), Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research will speak in a session titled “Improve Cancer Therapies Through Nano-Reformulation”

    Session Information:

    The Nanotechnology Characterization Laboratory’s (NCL) primary focus is the translation of nanotechnology formulations for cancer treatment. NCL has assisted nearly 100 different investigators and provided a range of characterization services (e.g. physicochemical, in vitro immunotoxicology, and in vivo animal studies) for over 300 different nanoformulations. Most cancer drugs are highly hydrophobic and have a multitude of dose-limiting toxic side effects. Nano-reformulation of these same drugs has proven potential to improve drug solubility, serve as a depot for controlled release, improve bioavailability and biodistribution, as well as reduce toxic side effects. This talk will provide a discussion of the benefits of nanotechnology reformulation to improve existing cancer therapies. Funded by NCI contract No. HHSN261200800001E.

    • Nanotechnology has been successful in helping dozens of drugs reach clinical trials and the commercial market.

    • Nanoformulation can improve efficacy and reduce side effects of existing treatments.

    • The NCL has a variety of reformulation and characterization options available to assist researchers in the advancement of their novel drugs or formulations.

    Continue reading:

    Nov 18, 2014 by Ryan Geswell